Recap: Vaxxinity Q3 Earnings
Portfolio Pulse from Benzinga Insights
Vaxxinity (NASDAQ:VAXX) reported its Q3 earnings, beating estimated earnings by 16.67% with an EPS of $-0.1 versus an estimate of $-0.12. However, revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.04, which was followed by a 0.42% increase in the share price the next day.
November 08, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxxinity's Q3 earnings beat estimates, which could potentially lead to a short-term increase in share price, as was the case last quarter.
Vaxxinity's Q3 earnings beat estimates by 16.67%, which is a positive signal for investors. This could potentially lead to a short-term increase in share price, as was the case last quarter when the company beat EPS estimates and the share price increased by 0.42% the next day.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100